Effect of anti-inflammatory (IL-4, IL-10) cytokine genes in relation to risk of cervical carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 6, 2012, Pages 514-519

  Shekari, Mohammad ^a,c   Kordi Tamandani, Dor Mohammad ^b,c   Malekzadeh, Kianoosh ^a,c   Sobti, Ranbir Chander ^c   Karimi, Samieh ^a   Suri, Vanita ^d  

^a HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF SISTAN AND BALUCHESTAN   (Iran)

^c PANJAB UNIVERSITY   (India)

^d POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

cervical cancer; IL 10; IL 4; oral contraceptive; smoking

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 4; ORAL CONTRACEPTIVE AGENT;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PASSIVE SMOKING; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UTERINE CERVIX CARCINOMA; VARIABLE NUMBER OF TANDEM REPEAT;

ADENOCARCINOMA; ADULT; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; CONTRACEPTIVES, ORAL; FEMALE; GENOTYPE; HUMANS; INDIA; INTERLEUKIN-10; INTERLEUKIN-4; MIDDLE AGED; MINISATELLITE REPEATS; ODDS RATIO; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; TOBACCO SMOKE POLLUTION; UTERINE CERVICAL NEOPLASMS;

EID: 84870255057     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31822d9c12     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 CA Cancer J Clin. 2005;55:74-108.
2. Baseman G, Koutsky LA. The epidemiology of Human Papillomavirus infections. J Clin Virol. 2005;32(suppl 1):16-24.
3. Burd EM. Human papillomavirus and cervical cancer. Clin Microbial Rev. 2003;16:1-17. (Pubitemid 36114705)
4. Calhoum ES, Mcgovern RM, Jannery CA, et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem. 2002;48: 1218-1224.
5. Spellberg B, Edwards JE. Type1, Type2 immunity in infections disease. Clin Infect Dis J. 2001;32:76-102.
6. Tepper RI, Coffman RL, Leder P. An eosinophil dependent mechanism of the anti tumour effect of IL-4. Science. 1992;257: 548-581.
7. Toi M, Harris AL, Bicknell R. IL-4 is a potent mitogen for capillary endothelium. Biochem Biophys Res Commun. 1992;174: 1287-1293.
8. Vokes EE, Figlin R, Hochster H, et al. A phase II study of recombinant human IL-4 for advanced or recurrent non-small cell lung cancer. Cancer J Sci Am. 1998;4:46-51.
9. Rasouli M, Kiany S. Association of IFN-g and IL-4 gene polymorphisms with susceptibility to brucellosis in Iranian patients. Cytokine. 2007;38:49-53. (Pubitemid 46990925)
10. Sai T, Chen WC, Tsai CH, et al. IL-4 gene, but not the IL-1 b gene polymorphism, is associated with oral cancer. Clin Lab Anal. 2005;19:93-98.
11. Fuu-Jen T, Chao HC, Chang-Chung C, et al. Interleukin-4 gene intron-3 polymorphism is associated with transitional cell carcinoma of the urinary bladder. BJU Int. 2005;95:432-435.
12. Eskdale J, Kube D, Tesch H, et al. Mapping of the human IL-10 gene and further characterization of the 50-flanking sequence. Immunogenetics. 1997;46:120-128. (Pubitemid 27234709)
13. Kim JM, Brannan CI, Copeland NG, et al. Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J Immunol. 1992;19:683-765.
14. Kube D, Platzer C, Von Knethen A, et al. Isolation of the human interleukin-10 promoter: Characterization of the promoter activity in Burkit's lymphoma cell lines. Cytokine. 1995;7:1-7.
15. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19: 683-765. (Pubitemid 32368050)
16. Edwards Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predict initial response to chronic hepatitis C to interferon-a. Hepatology. 1999;30:243-249.
17. Shrestha S, Wang C, Aissani B, et al. Interleukin-10 polymorphisms and human papillomavirus clearance among immunosuppressed adolescents. Cancer Epidemiol Biomarkers Prev. 2007; 16:1626-1632. (Pubitemid 47294829)
18. Clerici M, Searer GM, Clerici E. Cytokine dysregulation in invasive cervical carcinomas and other human neoplasias: Time to consider the Th1/Th2 pardigm. J Natl Cancer Inst. 1998;90: 261-266.
19. Gruijl TD, Bontkes HJ, Vanden Muysenberg AJC, et al. Difference in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur J Cancer. 1999; 35:490-497. (Pubitemid 29157871)
20. Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC multicentric case-control study. Lancet. 2002; 359:1085-1092. (Pubitemid 34270731)
21. Castellsague X, Munoz N. Chapter 3: COFACTORS in humanpapillomavirus carcinogenesis: Role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;20-28.
22. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: a Laboratory Manual. 3rd ed. Cold Spring Harbor, New York: COLD Spring Harbor Laboratory Press; 2001.
23. Wu MC, Huang CM, Tsai JJ, et al. Polymorphisms of IL-4 gene in Chinese patients with systemic lupus erythomatosis in Taiwan. Lupus. 2003;12:21-25. (Pubitemid 36172658)
24. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur Immunogenet. 1997;24:1.
25. Bidwell J, Keen L, Gallagher G, et al. Cytokine gene polymorphisms in human disease: On-line databases. Genes Immun. 1999;1:3-19. (Pubitemid 129622776)
26. Haukim N, Bidwell JL, Smith AJ, et al. Cytokine gene polymophism in human disease: Online data bases, supplement. Gene Immun. 2002;3:313-330. (Pubitemid 38967559)
27. Hausen HZ. Papillomavirus causing cancer: Evasion from host-cell in early events in carcinogenesis. J Natl Cancer Inst. 2002;92:690-698.
28. Sibata N, Ohnuma T, Takahashi T, et al. Polymorphism on risk of Alzheimer disease: Geneotype-phenotype association study in Japonese cases. Am J Med Genet. 2002;114:436-439. (Pubitemid 34525242)
29. Paul WE. Interleukin-4: A prototypic immunoregulatory lymphokine. Blood. 1991;77:1859-1870.
30. Brown MA, Hural J. Functions of IL-4 and control of its expression. Crit Rev Immunol. 1997;17:1-32. (Pubitemid 27068806)
31. Seno H, Satoh K, Tsuji S, et al. Novel interleukin-4 and interleukin-1 receptor antagonist gene variations associated with non-cardia gastric cancer in Japan: Comprehensive analysis of 207 polymorphisms of 11 cytokine genes. J Gastroenterol Hepatol. 2007;22:729-737. (Pubitemid 46608392)
32. Hunt PJ, Marshall SE, Weetman AP, et al. Cytokine gene polymorphisms in autoimmune thyroid disease. J Clin Endocrinol Metab. 2000;85:1984-1988. (Pubitemid 32269309)
33. Zhu S, Chan-Yeung M, Becker AB, et al. Polymorphisms of the IL-4, TNF-alpha, and Fc epsilon RI beta genes and the risk of allergic disorders in at-risk infants. Am J Respir Crit Care Med. 2000;161:1655-1659. (Pubitemid 30329044)
34. Yao-Yuan HS, Chi-Chen C, Fuu-Jen T, et al. Polymorphisms for IL-4-590 promoter, IL-4 intron-3 and TNF-a 308 promoter: Non-association with endometriosis. J Clin Lab Anal. 2002;66: 121-126.
35. Ju WR, Moon HK, Sang SS, et al. Interleukine-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett. 2002;184:57-63.
36. Roh JW, Kim MH, Seo SS, et al. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett. 2002;184:57-63. (Pubitemid 34718107)
37. Zoodsma M, Nolte IM, Schipper M, et al. Interleukin-10 and Fas poloymorphisms and susceptibility for pre-neoplastic cervical disease. Int J Cancer. 2007;15:282-290. (Pubitemid 43096595)
38. Stanczuk GA, Sibard EN, Tswana SA, et al. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer. 2001;94: 7921-7924.